Loading...
XWAR
KRK
Market cap9.40bUSD
Jun 19, Last price  
1,122.00PLN
1D
-0.36%
1Q
12.65%
Jan 2017
352.42%
Name

Krka dd Novo Mesto

Chart & Performance

D1W1MN
XWAR:KRK chart
P/E
22.89
P/S
4.28
EPS
11.52
Div Yield, %
3.12%
Shrs. gr., 5y
-0.62%
Rev. gr., 5y
5.04%
Revenues
2.04b
+6.94%
1,010,021,0001,075,627,0001,143,301,0001,200,827,0001,191,614,0001,164,607,0001,174,424,0001,266,392,0001,331,858,0001,493,409,0001,534,941,0001,565,802,0001,717,453,0001,806,391,0001,909,544,0002,042,018,219
Net income
403m
+13.01%
171,025,000162,801,000159,915,000172,836,000166,221,000158,245,000108,452,000152,600,000174,585,000245,545,000290,995,000309,214,000363,296,000313,946,000356,986,000403,432,225
CFO
530m
+46.97%
181,516,000247,058,000278,329,000302,751,000170,870,000277,941,000213,492,000227,827,000289,952,000349,523,000360,759,000386,097,000467,651,000227,254,000360,933,000530,479,020
Dividend
Jul 22, 202535.16562 PLN/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Krka, d. d. is a leading generic pharmaceutical enterprise primarily involved in the research, production, promotion, and sale of various pharmaceutical goods. Its market presence spans Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and numerous other international territories. The company's offerings are categorized into prescription medications, over-the-counter products, and veterinary health solutions. Its prescription drug pipeline targets a broad spectrum of medical conditions, including cardiovascular disorders, gastrointestinal issues, central nervous system ailments, pain management, anti-infective treatments, conditions affecting blood and blood-forming organs, urological problems, diabetes, and oncology. The array of non-prescription items includes products for oral and throat care, cough and cold remedies, analgesics, nasal preparations, vitamin and mineral supplements, products designed to enhance cerebral and peripheral circulation, digestive aids, and various general healthcare products. Furthermore, Krka supplies animal health products such as anti-infectives, antiparasitics, and other specialized formulations for both livestock and companion animals. Beyond its pharmaceutical operations, the company also provides health resort and tourist services. Krka, d. d. was established in 1954 and has its corporate headquarters in Novo Mesto, Slovenia.
IPO date
Feb 10, 1997
Employees
11,653
Domiciled in
SI
Incorporated in
SI

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT